By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Algeria is continuing its efforts to lower the cost of importing medicines that have been used for a number of years.
Algeria’s pharmaceutical industry is in a strong position to export. It is one of Algeria’s best-developed industries, and its assets enable it to rapidly transition to export, particularly to Africa.
The public authorities have set themselves the goal of achieving national drug needs and developing local production of all drugs in order to reduce dependence on foreign labs.
The Algeria Pharmaceutical Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Algeria produced biosimilar medicines for the first time: derived from living things. By focusing Frater Razes production on biosimilars and the production of products from cell culture, they have anticipated this trend in the same way that international laboratories have done through pharmaceutical innovation.
For the past two decades, this item had been imported. They have ensured Algerian patients’ self-sufficiency for the nation.
The laboratory intends to expand its exports right now. However, a further step toward self-sufficiency is another priority, and the company anticipates soon being able to synthesize organic substances as a result of its research.
They will produce their own raw materials, guarantee biosynthesis, and complete the manufacturing from A to Z. The country has undergone a paradigm shift as a result of a number of reforms, with health products becoming a growth engine rather than an economic burden.
